Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at the Guggenheim Genomic Medicines & Rare Disease Day on March 31, 2022, at 11:00 AM ET. Investors can access the live webcast and archived recordings on the company’s investor relations website.
This presentation aligns with Centessa's mission to develop impactful medicines across various therapeutic areas, including oncology, hematology, and neuroscience. For more details, visit Centessa's website.
Positive
- None.
Negative
- None.
News Market Reaction – CNTA
In the trading session that priced this news, CNTA gained 1.33%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time.
Access to the live webcast of this event, as well as archived recordings, will be available under the “Events” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc (“Centessa”) aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. Centessa’s programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. For more information, visit www.centessa.com.
Contacts:
Investors:
John Fraunces, LifeSci Advisors
Media:
